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Synthesis of 4-thio-5-(200-thienyl)uridine and
cytotoxicity activity against colon cancer cells in
vitro†
Xiaohui Zhang,a Depeng Li,a Jianzhong Qin,b Yaozhong Xu*c and Kedong Ma*a
A novel anti-tumor agent 4-thio-5-(200-thienyl)uridine (6) was synthesized and the in vitro cytotoxicity
activity against mice colon cancer cells (MC-38) and human colon cancer cells (HT-29) was evaluated by
MTT assay. The results showed that the novel compound had antiproliferative activity toward MC-38 and
HT-29 cells in a dose-dependent manner. The cell cycle analysis by ﬂow cytometry indicated that
compound 6 exerted in tumor cell proliferation inhibition by arresting HT-29 cells in the G2/M phase. In
addition, cell death detected by propidium iodide staining showed that compound 6 eﬃciently induced
cell apoptosis in a concentration-dependent manner. Moreover, the sensitivity of human ﬁbroblast cells
to compound 6 was far lower than that of tumor cells, suggesting the speciﬁc anti-tumor eﬀect of 4-
thio-5-(200-thienyl)uridine. Taken together, novel compound 6 eﬀectively inhibits colon cancer cell
proliferation, and hence would have potential value in clinical application as an antitumor agent.
1. Introduction
The ow of genetic information is directed by nucleic acids
(DNA and RNA). The base analogues structurally similar to the
four canonical bases can be incorporated into DNA, which alter
their properties and facilitate basic studies of DNA-related
processes such as its interaction with proteins, replication
and transcription.1,2 Structural modication of nucleosides is
biologically meaningful, and has led to the discovery of a variety
of new therapeutic agents, which includes antiviral and anti-
cancer agents. Pyrimidines and fused pyrimidines, being an
integral part of DNA and RNA have considerable chemical and
pharmacological importance. Thio-pyrimidine compounds in
which an oxygen atom in the base is replaced by sulfur have
been reported to show improved anti-cancer activity and
immune enhancement.3–7
Thiophene and its derivatives as important sulfur-
containing ve-member heterocyclic compounds have various
biological and pharmacological properties in terms of antimi-
crobial and antitumor activities.8–10 As a rich electronic aromatic
ring compound, the charge density of thiophene is greater than
that of benzene ring, and thus, it is easy for thiophene to occur
the p–p interactions. Moreover, the sulfur atom in thiophene is
certain nucleophilic and easy to interact with electrophilic
receptors or form metal or metal ion. From the viewpoint of
reducing the drug side eﬀects, enhancing the drug targeting
and improving the pharmacokinetic properties of drugs and the
corresponding therapeutic index, new compound with the
characteristics of both thiophene and thio-pyrimidine are
certainly with explore as attractive antitumor agent.11,12
Colon cancer is a kind of digestive tract malignant tumor,
commonly occurring at the junction of the rectum and sigmoid
colon. The incidence of colon cancer begins to rise at age 40 and
peaks at age 60 to 75, and the main life-style related cause is
high-fat diet and inadequate cellulose intake. Colon cancer
ranks third among the leading causes of cancer-associated
death aer lung and prostate cancer for men and aer lung
and breast cancer for women.13 In recent years, there is an
upward trend in China as the improvement of people's living
standard and changes in diet. Accordingly, the development of
novel chemotherapeutic agents is an urgent issue.
In this study, a novel 4-thio-5-(200-thienyl)uridine (6)
compound was synthesized by introducing a thiophene to
uridine by a series of reaction (Scheme 1). The cytotoxicity of
compound was evaluated by in vitro administering to mice
colon cancer cells line (MC-38) and human colon cancer cells
line (HT-29) by MTT assay, respectively. Compound 6 was found
to have antiproliferative activity against colon cancer cells.
Flow cytometry examination revealed that compound 6 inhibi-
ted cell growth through cell cycle arrest at G2/M phase.
Combined with no cytotoxic and apoptotic eﬀect on human
broblast cells, 4-thio-5-(200-thienyl)uridine (6) have potential
clinical applications.
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2. Experimental section
2.1. Apparatus and materials
Reagents were obtained from commercial suppliers and were
used without further purication. Melting point was deter-
mined on a XR-4-type micro-melting point detector, and was
uncorrected. The compounds synthesized were puried by
column chromatography using silica gel (200–300 mesh) except
for recrystallization and thin-layer chromatography (TLC) using
silica gel 60 F254 plates (250 mm; Qingdao Ocean Chemical
Company, China). IR spectra were recorded using a Nicolet 550
Spectrophotometer (4000–400 cm1) with a crystalline sample
spread on KBr pellets. UV spectra were recorded using UV-vis
spectrophotometer (JASCO, Japan); 1H NMR and 13C NMR
spectra were obtained by a 500 MHz Bruker AV-400 spectrom-
eter with TMS as an internal standard. The mass spectrum was
obtained on Hewlett-Packard 1100 LC/MSD spectrometer.
2.2. Crystal structure
The crystallographic data for 4-thio-5-(200-thienyl)uridine were
summarized in Table 1. X-ray diﬀraction data were collected at
120 K using a Bruker Nonius Kappa CCD diﬀractometer
mounted at the window of a Bruker FR591 rotating anode (Mo
Ka, l ¼ 0.71073 A˚) and equipped with Bruker APEX II detector
and Oxford Cryosystems Cryostream device. ORTEP views of 4-
thio-5-(200-thienyl)uridine were given in Fig. S4.† The structure
was solved by direct methods using SHELXS97.22 The crystal
structure has been deposited in Cambridge Structural Data-
base: CCDC depository number 1479957.
2.3. Synthesis and characterization of 4-thio-5-(200-thienyl)
uridine and its intermediates (1–6)
2.3.1. Acetyl protected uridine (2). The nucleoside (uridine,
1) (4.09 mmol) was dissolved in anhydrous pyridine (12 mL),
and then dry acetic anhydride (2.75 mL, 29 mmol) was added
under ice bath condition. The reaction was monitored by thin
layer chromatography. The reaction material point disappeared
aer about 5 h. The solvent was evaporated under reduced
pressure condition, and the residue was recrystallized from
ethanol to give white block crystal of acetyl protected pyrimi-
dine (2). Yield 99%; mp: 126–129 C (lit. mp: 127–129 C).23 1H
NMR (400 MHz, CDCl3) d: 9.48 (brs, 1H, NH), 7.41 (d, J ¼ 8.16
Hz, 1H, 6 H), 6.05 (d, J ¼ 4.76 Hz, 1H, 10-H), 5.80 (d, J ¼ 8.16 Hz,
1H, 5H), 5.34–5.35 (m, 2H, 20-H, 30-H), 4.35–4.36 (m, 3H, 40-H, 50-
H), 2.11–2.15 (m, 9H, 3–OC]OCH3); IR (lm)/cm1: 1755,
1720 (C]O), 1694 (amide C]O), 1630 (C]C).
2.3.2. 5-Iodo-acetyl protected pyrimidine (3). A mixture of
acetyl protected nucleosides (2) (0.5 mmol), iodine (76 mg, 0.3
mmol), ceric ammonium nitrate (CAN) (137 mg, 0.25 mmol)
and MeCN (8 mL) was stirred at 80 C for 1 h. The reaction
progress was monitored by TLC (solvent CH3Cl/acetone 4 : 1).
The solvent was evaporated and the residue was partitioned in
a cold mixture of EtOAc (20 mL), saturated NaCl/H2O (10 mL),
NaHSO3/H2O (5mL). Then, the aqueous layer was extracted with
EtOAc (10 mL  2). The organic layer was collected and washed
carefully using 5% cold NaHSO3/H2O (5 mL), then followed by
saturated NaCl/H2O (15 mL) and H2O (15 mL  2), nally dried
by anhydrous magnesium sulfate to remove water. The crude 5-
iodo products were puried by column chromatography or
recrystallized to give the target compound (3) with the yield
around 97%, mp: 175–176 C (lit. mp: 177–178 C). 1H NMR
(400 MHz, DMSO-d6) d: 11.83 (brs, 1H, NH), 8.18 (s, 1H, 6-H),
5.88 (d, J ¼ 4.0 Hz, 1H, 10-H), 5.47 (dd, J ¼ 8.0 Hz, 1H, 20-H),
5.33–5.35 (m, 1H, 30-H), 4.31–4.36 (m, 1H, 40-H), 4.21–4.27 (m,
2H, 50-H), 2.06, 2.07, 2.08 (3 s, 3H, 3H, 3H, OAc); UV (in CH3CN):
lmin ¼ 257.0 nm, 226.5 nm.
2.3.3. 5-(200-Thienyl)-acetyl-protected nucleoside (4). Bis-
(triphenylphosphine) palladium(II) chloride (0.016 g, 0.023
mmol) and tributyl-thiophene-2-yl-stannane (3.42 mmol) was
Scheme 1 Synthetic route of 4-thio-5-(200-thienyl)uridine.







Unit cell dimensions a ¼ 14.5426(10) A˚, a ¼ 90
b ¼ 7.8358(5) A˚, b ¼ 98.267(2)
c ¼ 50.555(4) A˚, g ¼ 90
Volume 5701.4(7) A˚3
Z 16
Density (calculated) 1.637 mg m3
Absorption coeﬃcient 0.404 mm1
F(000) 2928
Crystal Cut blade; yellow
Crystal size 0.170  0.090  0.030 mm3
q range for data collection 2.306–27.512
Index ranges 18 # h # 18, 10 # k # 10,
64 # l # 65
Reections collected 69 998
Independent reections 25 854 [Rint ¼ 0.0589]
Goodness-of-t on F2 1.031
Final R indices [F2 > 2s(F2)] R1 ¼ 0.0469, wR2 ¼ 0.1208
R indices (all data) R1 ¼ 0.0562, wR2 ¼ 0.1265
Absolute structure parameter 0.02(3)
Extinction coeﬃcient n/a
Largest diﬀ. peak and hole 0.775 and 0.402 e A˚3





















































































added to the solution of 5-iodo-acetyl protected nucleosides (3)
(1.14 mmol) which dissolved in anhydrous and peroxide-free
1,4-dioxane (30 mL) under argon atmosphere, the mixture was
heated at 90 C and reuxing for 3 h (TLC tracking reaction).
Aer cooling down, the black solid was ltered through celite to
remove the solvent. Silica gel chromatography (10% CH3OH/
CH2C12) yielded white solid compound with yield of around
93%, namely 5-(200-thienyl)-acetyl protected nucleoside (4). Mp:
178–181 C. 1H NMR (400 MHz, DMSO-d6) d: 11.83 (brs, 1H,
NH), 8.17 (s, 1H, 6-H), 7.46–7.50 (m, 2H, 500-H, 300-H), 7.07 (m,
1H, 400-H), 5.94–5.95 (d, 1H, J ¼ 4.0 Hz, 10-H), 5.57–5.60 (t, 1H, J
¼ 12.0 Hz, 30-H), 5.34–5.39 (m, 1H, 20-H), 4.25–4.36 (m, 3H, 40-H,
50-H), 2.04–2.06 (m, 9H, CH3);
13C NMR (DMSO-d6, 500 MHz) d:
170.49, 169.83, 169.79 (3–C]O), 137.27 (C-4), 126.92 (C-2),
126.71 (C-200), 124.02 (C-500), 109.51 (C-6), 89.28 (C-400), 79.75
(C-300), 79.64 (C-5), 72.51 (C-40), 72.44 (C-10), 70.07 (C-30), 69.95
(C-50), 63.44 (C-20), 20.97, 20.77, 20.71 (3–CH3); HRMS: [M +
Na]+ 475.0790, calculated for C19H20N2O9SNa; found 475.0793.
UV-vis (in CH3CN): lmax/nm: 262.0, 304.0. IR (lm)/cm
1: 1748.0
(C]OCH3), 1717.5 (C]O), 1459.4, 1374.3 (NH), 1571.3, 1414.0,
1299.8 (C]C), 1627.47 (C5]C6).
2.3.4. 4-Thio-5-(200-thienyl)-acetyl protected nucleoside (5).
5-(200-Thienyl)-acetyl protected nucleoside (4) (2.32 mmol) were
dissolved in peroxide-free 1,4-dioxane (50 mL), then P2S5 (1.0
g, 4.50 mmol) was added. The mixture was reuxed for 3–4 h
when TLC analysis showed complete disappearance of the
starting material. The solvent was removed under reduced
pressure and the residue was treated with CH2Cl2 for several
times. The residue was separated on a silica gel column,
eluting with petroleum : ethyl acetate (3 : 2, v/v) to give the title
compound (5) at yield of 56%. Mp: 171–173 C. 1H NMR (400
MHz, DMSO-d6) d: 13.07 (brs, 1H, NH), 8.05 (s, 1H, 6-H), 7.57–
7.58 (d, 1H, J ¼ 4.0 Hz, 500-H), 7.29–7.30 (d, 1H, J ¼ 4.0 Hz, 300-
H), 7.06–7.08 (t, 1H, J ¼ 4.0 Hz, 30-H), 5.35–5.41 (m, 1H, 20-H),
4.25–4.36 (m, 3H, 40-H, 50-H), 2.07 (m, 9H, CH3);
13C NMR
(DMSO-d6, 500 MHz) d: 188.58 (C-4), 170.43, 169.78, 169.75
(3–C]O), 147.07 (C-2), 136.74 (C-200), 136.41 (C-500), 127.11
(C-6), 126.34 (C-400), 117.96 (C-300), 89.96 (C-5), 79.97 (C-40),
72.72 (C-10), 69.92 (C-30), 66.83 (C-50), 63.22 (C-20), 20.81, 20.77,
20.74 (3–CH3); HRMS: [M + H]+ 467.0741, calculated for
C19H20N2O8S2; found 469.0727. UV-vis (in CH3CN): lmax/nm:
239, 285, 348. IR (lm)/cm1: 1747.5 (C]OCH3), 1715.6 (C]
O), 1451.7, 1371.3 (NH), 1522.7, 1227.5, 1427.31 (C]C), 1610
(C5]C6), 1108 (C]S).
2.3.5. 4-Thio-5-(200-thienyl)-nucleoside (6). 4-Thio-5-(200-
thienyl)-acetyl protected nucleoside (5) (2.14 mmol) were sus-
pended in absolute MeOH (60 mL, 1.5 mmol) and saturated
with dry ammonia gas. The mixture was stirred at room
temperature for 4.5 h. The resulting solution was evaporated
under reduced pressure at 35 C and the residue was puried
on a silica gel column packed in (CH2Cl2 : MeOH 9 : 1, v/v) and
provide a solid product at yields of 45%, namely 4-thio-5-(200-
thienyl) nucleoside (6). Mp: 185–187 C. 1H NMR (400 MHz,
DMSO-d6) d: 12.89 (brs, 1H, NH), 8.51 (s, 1H, 6-H), 7.47–7.48
(d, 1H, J¼ 4.0 Hz, 500-H), 7.27–7.28 (m, 1H, 300-H), 6.98–7.00 (m,
1H, 400-H), 5.75–5.76 (d, 1H, J¼ 4.0 Hz, 10-H), 5.50–5.51 (d, 1H, J
¼ 4.0 Hz, OH), 5.30–5.32 (t, 1H, J ¼ 4.0 Hz, OH), 5.06–5.07 (d,
1H, J ¼ 4.0 Hz, 50-OH), 4.10–4.14 (m, 1H, 30-H), 4.00–4.04
(m, 1H, 20-H), 3.89–3.90 (m, 1H, 40-H), 3.56–3.72 (m, 2H, 50-H);
13C NMR (DMSO-d6, 500 MHz) d: 187.52 (C-4), 172.04 (C-2),
147.36 (C-200), 136.91 (C-500), 135.73 (C-6), 127.09 (C-400),
126.23 (C-300), 117.61 (C-5), 89.80(C-40), 85.20 (C-10), 74.87 (C-
30), 69.57 (C-50), 60.32 (C-20), HRMS: [M + Na]+ 365.0244,
calculated for C13H14N2O5S2Na; found 365.0249. UV-vis (in
CH3CN): lmax/nm: 239, 287, 356. IR (lm)/cm
1: 3344.3 (–OH),
1699.7 (C]O), 1519.0, 1280.8 (C]C), 1600.2 (C5]C6), 1122.6
(C]S).
2.4. Toxicity test on colon cancer cells
The MTT colorimetric method and ow cytometry were
employed to analyze the anti-tumor activity of 4-thio-5-(200-
thienyl)uridine on mice colon cancer cell line MC-38 and
human colon cancer cell line HT-29, which were purchased
from the American Type Culture Collection.
2.4.1. Cell antiproliferative activity assay. The proliferation
inhibitory activities of the synthesized target compounds was
evaluated using mouse and human colon tumor cell lines (MC-
38 and HT-29) by the MTT method in vitro. MC-38 and HT-29
cells were cultured in DMEM and RPMI1640 medium, 10%
fetal calf serum, 100 mg mL1 penicillin, and 100 mg mL1
streptomycin at 37 C under 5% CO2, respectively. Then the
cells were seed into 96-well plate at 1 104 cells per well and co-
incubated with 4-thio-5-(200-thienyl)uridine under diﬀerent
concentrations (nal concentration: 100 mM, 200 mM, 300 mM,
400 mM and 500 mM) for 24 h, respectively. At the end of this
time interval, 20 mL (5 mg mL1) MTT (3-(4,5 dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) was added to each well,
and aer incubation at 37 C for 4 h the MTT solution was
removed and 100 mL of dimethylsulfoxide (DMSO) was added to
dissolve the crystals. The absorbance of each well was measured
at 570 nm.
2.4.2. Cell cycle distribution and apoptosis analysis by ow
cytometry detection. Cell cycle distribution and apoptosis
analysis was conducted according to the reported procedure.24
Briey, the HT-29 cells were inoculated into a 6-well cell culture
plate at 5  105 cells per well and cultured overnight. Then, 2
mL of the culture medium containing diﬀerent concentrations
of 4-thio-5-(200-thienyl)uridine were added to each well respec-
tively and co-incubated for another 48 hours. Aerwards, the
cells oating in the supernatant were combined with the
adherent fraction, washed with phosphate buﬀered saline (PBS)
thrice, xed with cool ethanol, treated with RNase, and then
stained with propidium iodide (50 mg mL1) at 37 C in a dark
environment. The samples were immediately analyzed by ow
cytometry.
2.5. Statistical analysis
Data were presented as mean  SD of three independent
experiments. One-way analysis of variance (ANOVA) was per-
formed on the data to assess the impact of the variables on the
results. SPSS 13.0 statistical soware (SPSS Inc., Chicago, USA)
was used for the statistical analysis of all data. A p value of
#0.05 was considered to be statistically signicant.





















































































3. Results and discussion
3.1. Chemistry synthesis
3.1.1. Synthetic route to 4-thio-5-(200-thienyl)uridine. The
synthetic route to the target 4-thio-5-(200-thienyl)uridine was
depicted in Scheme 1. The starting uridine 1 was rst acetylated
at its 20-, 30- and 50-positions to produce the acetylated
compound 2. The compound 3, an important intermediate was
easily synthesized via iodine and CAN (ceric ammonium nitrate)
in MeCN. Then, the synthesis of compound 4 was carried out
through palladium catalyzed stille cross coupling reaction to
produce the thien-conjugated uridine 4 with a yield of over
90%.14–17 Next, compound 5 was prepared according to the re-
ported procedure with some modication.18,19 Finally the pro-
tecting groups were removed with ammonia in methanol to
produce 4-thio-5-(200-thienyl)uridine 6with good yields. Aer the
target compound was successfully prepared, structural charac-
teristics of the compound were examined on UV, MS and NMR
spectroscopies, the results were shown in ESI (Fig. S1–S3†).
3.2. Cytotoxicity activities
3.2.1. Anti-proliferative activity of compound 6 against
mouse colon cancer cell MC-38 in vitro. The cytotoxic eﬀect of
the prepared compound was evaluated against mouse colon
cancer cell MC-38. The MC-38 cell line was treated with
compound 6 (nal concentrations: 100, 200, 300, 400, 500 mM)
for 48 h, and the viable cells were measured by a MTT assay. As
shown in Fig. 1, the cell growth inhibition was observed under
diﬀerent concentration of 4-thio-5-(200-thienyl)uridine. At a low
concentration of 100 mM, the cell survival rate dropped to
around 65%, then gradually declined at a slower rate along with
the increase of compound concentration, nally reached the
minimal value of 44% at 500 mM, suggesting that 4-thio-5-(200-
thienyl)uridine induced a dose-dependent proliferation inhibi-
tion of MC-38 cells. Additional increase in dosage did not
further decrease the cell survival rate, and no signicant cell
death was detected and maintained at a relatively stable state
(data not shown). The variance analysis data suggested that
compound 6 had signicant inhibitory inuence on MC-38 cell
growth (p < 0.03). In comparison of the adjacent low-dose
groups, only the 200 mM group showed signicant diﬀerence
(p < 0.05) from the adjacent groups in the inhibition of MC-38
cell growth, while no signicant diﬀerences were found
between the remaining groups, exhibiting a slow anti-
proliferative trend of the target compound along with the
increase of concentrations.
3.2.2. Anti-proliferative activity against human colon
cancer cells HT-29. The in vitro proliferation inhibitory activity
of the prepared compounds was evaluated against the human
colon cancer cell HT-29. Aer 48 h treatment under diﬀerent
concentrations (nal concentrations: 100, 200, 300, 400, 500
mM), MTT assay was adopted to examine the cell survival rate. As
shown in Fig. 2, compound 6 exhibited low antiproliferative
activities at 100 mM level, with cell viability of 92%. However, the
numbers of living cells considerably decreased accompanied
with the concentration increase of compound, and reached the
minimal value of approximately 43% at 500 mM level, suggesting
that compound 6 induced dose-dependent proliferation inhi-
bition of HT-29 cells. Subsequent increases in dosage did not
further reduce the HT-29 cell survival rate, but rather main-
tained at a relatively stable state (data not shown). The variance
analysis of the data suggested that the title compound exerted
a signicant antiproliferative activity against HT-29 cell from
concentration of 200 mM (p < 0.001). In addition, the signicant
diﬀerence between the test and adjacent low-dose groups
indicated that the inhibitory eﬀect considerably enhanced when
the compound 6 concentrations was elevated (p < 0.01).
Fig. 2 Antiproliferative eﬀect of compound 6 on HT-29 cells. Data are
expressed as mean  SD and evaluated by analysis of variance
(ANOVA). Results are representative of three replicates. *Compared
with the control group, p < 0.001, **compared with the adjacent low-
dose groups, p < 0.01.
Fig. 1 Antiproliferative eﬀect of compound 6 onMC-38 cells. Data are
expressed as mean  SD and evaluated by analysis of variance
(ANOVA). Results are representative of three replicates. *Compared
with the control group, p < 0.03, **compared with the adjacent low-
dose groups, p < 0.05.





















































































3.2.3. Cell cycle distribution and apoptotic analysis using
ow cytometry. To probe the antiproliferative mechanism of 4-
thio-5-(200-thienyl)uridine in HT-29 cell, we extended our study
on investing the eﬀect of compound 6 on cell cycle progression.
The cells were cultured with diﬀerent concentrations of
compound 6 (0, 100 mM, 200 mM, 300 mM, 400 mM and 500 mM)
Fig. 3 Eﬀects of diﬀerent concentrations of compound 6 on cell cycle distribution of HT-29. The experiment was repeated thrice. Here only
representative ﬂow cytometric graphs are shown.





















































































for 24 h, then subjected to ow cytometry to examine the cell
cycle distribution. As showed in Fig. 3 and 4, low concentration
(100 mM) of compound 6 almost no inuence on cell cycle
progression, while higher concentration resulted in G2 phase
andmitosis arrest in a dose-dependent manner, which reected
by the population of cells in the G2/M phase increasing from
10.85% at 200 mM to 36.76% at 500 mM. On the other hand,
there was no signicant impact of compound 6 on the numbers
of cells at G1 phase and S phase. Since the cells in G2/M phase
had completed DNA replication (containing 4N DNA) and
entered the mitosis process, the accumulation of cells at this
stage implied that compound 6 plays an important role in
mitotic arrest.
In addition, a fraction of cell population with DNA content
lower than that of G1 (sub-G1 phase) gradually increased aer
exposure to compound 6, from 10.3% (control group) to 20.54%
(100 mM), 21.197% (200 mM), 31.47% (300 mM), 40.46% (400
mM), and 44.63% (500 mM), respectively. As the DNA replication
had not yet occurred at G1 phase, the total DNA content lower
than the value in G1 phase indicated the occurrence of DNA
degradation in the cell, which commonly was considered as an
important feature of cell apoptosis.20,21 Therefore, the increase
of cell numbers at the sub-G1 phase revealed that compound 6
could induce apoptosis of HT-29 cell at such low concentration
of 100 mM. Meanwhile, the population of apoptotic cells
elevated under higher concentration, suggesting the apoptosis
induction occurred in a dose-dependent manner. These results
indicated that cell cycle arrest in the G2/M stage and apoptosis
induction was important factors by which compound 6 exerted
its inhibitory eﬀects on HT-29 cells.
3.2.4. Anti-proliferative activity against normal human
broblasts. The ideal anti-cancer drug should target tumors
specically while causing minimal side eﬀects. The impact of
the drug on normal cell proliferation was one of the key
checkpoints in determining its specic anti-tumor activity and
side eﬀect prole. Therefore, we extended our study on exam-
ining the eﬀects of diﬀerent concentrations of compound 6 on
the proliferation of broblast cells. Aer 48 hours of drug
treatment under diﬀerent concentrations, MTT was added to
the broblast cells. The OD values were measured and the cell
proliferation rates were calculated. The results obtained
revealed that the sensitivity of normal human broblast cells to
compound 6 were lower than that of tumor cells, and higher
concentration gave no inuence on cell proliferation (Fig. 5),
indicating that 4-thio-5-(200-thienyl)uridine is a promising agent
with specic anti-tumor eﬀect.
4. Conclusions
In this study, we successfully synthesized a novel compound: 4-
thio-5-(200-thienyl)uridine (6) by connecting thiophene to 5-
position of thiopyrimidine. In vitro pharmacological analysis
demonstrated the compound 6 exerted proliferation inhibitory
activity against MC-38 and HT-29 cells by arresting cell cycle at
the G2/M phase and inducing apoptosis in a dose-dependent
manner. The sensitivity of the normal human broblasts to
compound 6 was found to be substantially lower than that of
the tumor cells and diﬀerent concentrations showed no
signicant inhibition of normal broblast proliferation, sug-
gesting that 4-thio-5-(200-thienyl)uridine (6) and its analogues
would be promising candidates for anti-tumor drug
development.
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